A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
← catalyst calendarNCT07722546 · readout in 530 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
60estimated
Sites
3
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-30 | actual | When the study began enrolling |
| Primary completion | 2028-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Graves' Disease
Interventions
- Drug: Felzartamab — also filed as BIIB148, MOR202, MOR03087, TJ202
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants who are Euthyroid and off Anti-Thyroid Drugs (ATD) at Week 24
measured At Week 24
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed